Brokerages Set Solventum Co. (NYSE:SOLV) Target Price at $68.00

Shares of Solventum Co. (NYSE:SOLV) have been given an average recommendation of “Hold” by the ten research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $68.00.

Several research firms have recently weighed in on SOLV. Morgan Stanley lifted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. BTIG Research initiated coverage on shares of Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. The Goldman Sachs Group upped their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Wolfe Research initiated coverage on shares of Solventum in a research note on Thursday, September 26th. They set a “peer perform” rating for the company. Finally, Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th.

Solventum Stock Performance

Solventum stock opened at $70.81 on Thursday. The firm’s fifty day moving average is $70.53 and its 200 day moving average is $62.33. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum has a 52-week low of $47.16 and a 52-week high of $96.05.

Institutional Trading of Solventum

A number of institutional investors have recently made changes to their positions in SOLV. Davis Selected Advisers acquired a new stake in Solventum in the second quarter worth about $273,070,000. Nuance Investments LLC purchased a new position in shares of Solventum in the 2nd quarter valued at approximately $115,829,000. Newport Trust Company LLC acquired a new stake in Solventum in the 2nd quarter worth approximately $98,976,000. Baupost Group LLC MA purchased a new stake in Solventum during the 2nd quarter worth approximately $96,242,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new position in Solventum during the 3rd quarter valued at approximately $125,488,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.